NasdaqCM - Nasdaq Real Time Price USD

Oncolytics Biotech Inc. (ONCY)

0.5715

+0.0215

+(3.91%)

As of 10:30:14 AM EDT. Market Open.

No Tool

Measure

UNDO

Redo

All

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for ONCY

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

Oncolytics Up 1.5% in U.S. Pre-market as Funds Pelareorep's Ongoing Clinical Development

Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

Oncolytics Biotech Inc (ONCY) Q4 2024 Earnings Call Highlights: Promising Cancer Study Results ...

Oncolytics Biotech Inc (ONCY) Q4 2024 Earnings Call Highlights: Promising Cancer Study Results ...

Oncolytics Q4 Net Loss Doubles, Provides Pelareorep Update

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

Oncolytics Biotech (ONCY) Loses -9.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Oncolytics Biotech (ONCY) Loses -9.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025

Oncolytics Biotech Receives German Clearance for Pancreatic Cancer Study

CRDF Cardiff Oncology, Inc.

2.7800

+2.58%

CANF Can-Fite BioPharma Ltd.

1.0600

+1.92%

BPTSY Biophytis S.A.

1.9400

0.00%

EYEN Eyenovia, Inc.

1.1250

-3.02%

APS.TO Aptose Biosciences Inc.

2.8000

-0.36%

MDNA.TO Medicenna Therapeutics Corp.

1.1900

-2.46%

CADL Candel Therapeutics, Inc.

5.04

+3.07%

SVA.TO Sernova Biotherapeutics Inc

0.2000

+2.56%

PTN Palatin Technologies, Inc.

0.2155

-1.15%

HOOK HOOKIPA Pharma Inc.

1.4600

+10.53%

Try again.